A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial

Simple item page
dc.contributor.buuauthorYazıcıoğlu, Bengi
dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorSarandol, Aslı
dc.contributor.buuauthorAkgöz, Semra
dc.contributor.buuauthorEker, Saygın
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridQ-9477-2019tr_TR
dc.contributor.scopusid25226441700tr_TR
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid14061863400tr_TR
dc.contributor.scopusid36341064200tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.date.accessioned2021-12-06T07:46:01Z
dc.date.available2021-12-06T07:46:01Z
dc.date.issued2006-09-30
dc.description.abstractThe aim of the study was to compare the efficacy and tolerability of the combination of reboxetine and sertraline to venlafaxine XR (extended release) in major depressive disorder (MDD). The study consisted of 40 patients with MDD, aged 18-65 years. Patients were evaluated six times during a 10-week period. Treatment was started as venlafaxine XR 75 mg/day once a day (od) or reboxetine 4 mg/day twice a day (bid)+ sertraline 50 mg/day od. In the second week, venlafaxine XR was increased to 150 mg/day od and reboxetine 8 mg/day bid while sertraline was kept at the same dose. The Hamilton Depression Rating Scale (HDRS), Montgomery and Asberg Depression Rating Scale, Clinical Global Impressions-Severity of Illness and Clinical Global Impression s-Global Improvement Scale were applied on each visit. Beginning from the second visit, both groups showed significant declines in each scale. There were no significant differences between treatment response rates. Remission rates defined as HDRS <= 10 were significantly higher in the venlafaxine XR group at visit 4 only. However, when remission was accepted as HDRS <= 7, no significant difference was observed. Side effect frequency was similar between the treatment groups. We may suggest that the reboxetine+ sertraline combination is not superior to venlafaxine treatment.en_US
dc.identifier.citationYazıcıoğlu, B. vd. (2006). ''A comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trial''. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(7), 1271-1276.en_US
dc.identifier.endpage1276tr_TR
dc.identifier.issn0278-5846
dc.identifier.issn1878-4216
dc.identifier.issue7tr_TR
dc.identifier.pubmed16820257tr_TR
dc.identifier.scopus2-s2.0-33747067089tr_TR
dc.identifier.startpage1271tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.pnpbp.2006.04.018
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0278584606001795
dc.identifier.urihttp://hdl.handle.net/11452/22999
dc.identifier.volume30tr_TR
dc.identifier.wos000240280000015tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.relation.journalProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectPsychiatryen_US
dc.subjectDepressionen_US
dc.subjectReboxetineen_US
dc.subjectSertralineen_US
dc.subjectVenlafaxineen_US
dc.subjectRemissionen_US
dc.subjectFluoxetineen_US
dc.subjectCitalopramen_US
dc.subjectAugmentationen_US
dc.subjectNonrespondersen_US
dc.subjectParoxetineen_US
dc.subjectResistanten_US
dc.subjectBupropion sren_US
dc.subjectDouble-blinden_US
dc.subjectSerotonin reuptake inhibitorsen_US
dc.subject.emtreeVenlafaxineen_US
dc.subject.emtreeSertralineen_US
dc.subject.emtreeReboxetineen_US
dc.subject.emtreeXerostomiaen_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeStatistical analysisen_US
dc.subject.emtreeSide effecten_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeMontgomery asberg depression rating scaleen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHamilton scaleen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeFlushingen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeDrug tolerabilityen_US
dc.subject.emtreeDrug induced headacheen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeConstipationen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeClinical global impression scaleen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeAnorgasmiaen_US
dc.subject.emtreeAgitationen_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAdulten_US
dc.subject.meshTime factorsen_US
dc.subject.meshSertralineen_US
dc.subject.meshSerotonin uptake inhibitorsen_US
dc.subject.meshMorpholinesen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshMaleen_US
dc.subject.meshHumansen_US
dc.subject.meshFemaleen_US
dc.subject.meshDrug interactionsen_US
dc.subject.meshAdolescenten_US
dc.subject.meshDrug evaluationen_US
dc.subject.meshAdrenergic uptake inhibitorsen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshDepressive disorder, majoren_US
dc.subject.meshCyclohexanolsen_US
dc.subject.scopusMorpholines; Reboxetine; Amino Alcoholsen_US
dc.subject.wosClinical neurologyen_US
dc.subject.wosNeurosciencesen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.subject.wosPsychiatryen_US
dc.titleA comparison of the efficacy and tolerability of reboxetine and sertraline versus venlafaxine in major depressive disorder: A randomized, open-labeled clinical trialen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus